Celldex Therapeutics, Inc. revenue by segment CLDX

Annual Quarterly

Celldex Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Grant at $1.4 million, 94% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
0
2
7
7
2
5
7
4
10
13
7
Grant
0
-98.1%
share 70.3%
1
-79.3%
share 93.7%
7
+6.1%
share 99.8%
7
+187.0%
share 96.0%
2
-50.2%
share 97.6%
5
-9.7%
share 99.3%
5
+65.1%
share 69.0%
3
share 86.8%
—
—
—
Services
0
-30.9%
share 29.7%
0
+646.2%
share 6.3%
0
-95.3%
share 0.2%
0
+396.4%
share 4.0%
0
+80.6%
share 2.4%
0
-98.7%
share 0.7%
2
+386.5%
share 31.0%
0
share 13.2%
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
CLDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Hampton, NJ
SEC filer status
Large accelerated filer
SEC CIK
744218
Former names
AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.